Skip to main content
. 2011 Mar 17;30(1):30. doi: 10.1186/1756-9966-30-30

Table 3.

Combined analysis of EGFR and KRAS status in NSCLC patients

Primary/Metastatic tumor
WT/WT WT/MUT MUT/WT MUT/MUT Discordance

EGFR 54 5 0 21* 7 case

KRAS 73 6 0 1 6 case

* E746-A750/L747-T751; L747-P753insS/R748-P752

Abbreviation: WT, wild type; MUT, mutational type